Journal of Substance Abuse Treatment

Article	Citations
Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine	93
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19	83
Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic	77
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder	75
A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose	71
Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19	66
Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings	60
Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study	57
Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study	57
A systematic review of stigma interventions for providers who treat patients with substance use disorders	55
Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use	45
COVID-19-related treatment service disruptions among people with single- and polysubstance use concerns	44
Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19	44
Online digital recovery support services: An overview of the science and their potential to help individuals with substance use disorder during COVID-19 and beyond	42
Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island	42
Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19	41
Telehealth sustains patient engagement in OUD treatment during COVID-19	41
Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms	39
Impacts of COVID-19 on residential treatment programs for substance use disorder	38
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?	37
Appointment wait-times and arrival for patients at a low-barrier access addiction clinic	36
The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19	36
Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?	35
Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic	34
Family involvement in treatment and recovery for substance use disorders among transition-age youth: Research bedrocks and opportunities	33

Experiences of racial discrimination in the medical setting and associations with medical mistrust and expectations of care among black patients seeking addiction treatment	32
COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings	31
Adolescent substance use: Challenges and opportunities related to COVID-19	31
Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities	30
Digital delivery of a contingency management intervention for substance use disorder: A feasibility study with DynamiCare Health	30
A scoping review of alcohol, tobacco, and other drug use treatment interventions for sexual and gender minority populations	29
Acute and extended exposure to episodic future thinking in a treatment seeking addiction sample: A pilot study	29
Difficult binds: A systematic review of facilitators and barriers to treatment among mothers with substance use disorders	29
Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic	29
Treatment barriers among individuals with co-occurring substance use and mental health problems: Examining gender differences	28
Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis	28
Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine	28
The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review	28
“You have to take this medication, but then you get punished for taking it:” lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period	28
“A good mother”: Impact of motherhood identity on women's substance use and engagement in treatment across the lifespan	27
One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission	27
A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, he	26
Patterns of substance use before and after hospitalization among patients seen by an inpatient addiction consult service: A latent transition analysis	26
Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis	26
A chance to do it better: Methadone maintenance treatment in the age of Covid-19	25
Hospitalization outcomes of people who use drugs: One size does not fit all	24
Predictors of premature treatment termination in a large residential addiction medicine program	24
Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder	24
Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic	24
How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic	24
Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?	24
Experiences of stigma in hospitals with addiction consultation services: A qualitative analysis of patients' and hospital-based providers' perspectives	23
Engaging the justice system to address the opioid crisis: The Justice Community Opioid Innovation Network (JCOIN)	23
Racial/ethnic and gender differences in receipt of brief intervention among patients with unhealthy alcohol use in the U.S. Veterans Health Administration	23
Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder	23
Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic	23
The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives	23
Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs	23
A smartphone-smartcard platform for contingency management in an inner-city substance use disorder outpatient program	22
Contingency management for treatment attendance: A meta-analysis	22
A feasibility study providing substance use treatment in the Black church	22
Patient-centered care's relationship with substance use disorder treatment utilization	22
Falling between two systems of care: Engaging families, behavioral health and the justice systems to increase uptake of substance use treatment in youth on probation	22
Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply	22
Low-barrier buprenorphine during the COVID-19 pandemic: A rapid transition to on-demand telemedicine with wide-ranging effects	21
Mobile methadone medication units: A brief history, scoping review and research opportunity	21
Adapting methadone inductions to the fentanyl era	21
Changes in methadone take-home dosing before and after COVID-19	21
Pilot trial investigating a brief behavioral economic intervention as an adjunctive treatment for alcohol use disorder	21
“No home to take methadone to”: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston	20
Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders	20
COVID-19 innovations in medication for addiction treatment at a Skid Row syringe exchange	20
A collision of crises: Addressing an HIV outbreak among people who inject drugs in the midst of COVID-19	20
Adoption of telemedicine services by substance abuse treatment facilities in the U.S.	20
Healthcare utilization patterns among persons who use drugs during the COVID-19 pandemic	20

Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program	20
With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic	19
Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)	19
Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016	19
A systematic literature review of clinical trials and therapeutic applications of ibogaine	19
Leveraging digital tools to support recovery from substance use disorder during the COVID-19 pandemic response	19
“In their mind, they always felt less than”: The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention	19
Substance use treatment in Appalachian Tennessee amid COVID-19: Challenges and preparing for the future	19
The intersection of race and opioid use disorder treatment: A quantitative analysis	19
Integrated substance use and prenatal care delivery in the era of COVID-19	18
Characterizing variability in state-level regulations governing opioid treatment programs	18
Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada	18
Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19	18
Exploring first responders' perceptions of medication for addiction treatment: Does stigma influence attitudes?	18
Comparing intentions to reduce substance use and willingness to seek help among transgender and cisgender participants from the Global Drug Survey	18
Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives	17
Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency	17
Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder	17
Legalization of cannabis use in Canada: Impacts on the cannabis use profiles of youth seeking services for substance use	17
Drug and alcohol treatment utilization and barriers among Black, American Indian/Alaskan Native, Latine, Asian/Pacific Islander/Native Hawaiian, and White adults: Findings from NESARC-III	17
Racial/ethnic disparities in the availability of hospital based opioid use disorder treatment	17
Peer recovery services for persons returning from prison: Pilot randomized clinical trial investigation of SUPPORT	17
Considering the harms of our habits: The reflexive urine drug screen in opioid use disorder treatment	17
Revising our attitudes towards agonist medications and their diversion in a time of pandemic	17
The Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN-PATHS): A hybrid type-1 effectiveness trial of enhanced primary care to improve opioid use d	17
Something to despair: Gender differences in adverse childhood experiences among rural patients	16
Sharp decline in hospital and emergency department initiated buprenorphine for opioid use disorder during COVID-19 state of emergency in California	16
The impact of naturalistic cannabis use on self-reported opioid withdrawal	16
Geographic access to buprenorphine prescribers for patients who use public transit	16
The role of perceived treatment need in explaining racial/ethnic disparities in the use of substance abuse treatment services	16
“They went down that road, and they get it”: A qualitative study of peer support worker roles within perinatal substance use programs	16
Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series	16
Providing addiction services during a pandemic: Lessons learned from COVID-19	16
Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting	16
COVID-19 and treating incarcerated populations for opioid use disorder	16
Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year	15
A Facebook intervention to address cigarette smoking and heavy episodic drinking: A pilot randomized controlled trial	15
Research on substance use disorders during the COVID-19 pandemic	15
Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: A qualitative study in Vancouver, Canada	15
The impact of trauma characteristics on post-traumatic stress disorder and substance use disorder outcomes across integrated and substance use treatments	15
Feasibility and acceptability of a digital health intervention to promote engagement in and adherence to medication for opioid use disorder	15
Telemedicine works for treating substance use disorder: The STAR clinic experience during COVID-19	15
Kentucky Women's Justice Community Opioid Innovation Network (JCOIN): A type 1 effectiveness-implementation hybrid trial to increase utilization of medications for opioid use disorder among justice-in	15
Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19	15
A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder	15
Bridge clinic buprenorphine program decreases emergency department visits	15
Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general prac	15
Overdose deaths from nonprescribed prescription opioids, heroin, and other synthetic opioids in Medicare beneficiaries	15
Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic	14
Facilitators and barriers to post-overdose service delivery in Rhode Island emergency departments: A qualitative evaluation	14
Parental status and characteristics of women in substance use treatment services: Analysis of electronic patient records	14
Health center implementation of telemedicine for opioid use disorders: A qualitative assessment of adopters and nonadopters	14
Recovering from substance use disorders during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City	14
Opioid overdose and inpatient care for substance use disorder care in Massachusetts	14
A pilot randomized clinical trial of Brief Behavioral Treatment for Insomnia to reduce problematic cannabis use among trauma-exposed young adults	14
“I have to be around people that are doing what I'm doing”: The importance of expanding the peer recovery coach role in treatment of opioid use disorder in the face of COVID-19 health disparities	14
Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic	14
Value of family involvement in substance use disorder treatment: Aligning clinical and financing priorities	14
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse	13
The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth	13
Caring for women with substance use disorders through pregnancy and postpartum during the COVID-19 pandemic: Lessons learned from psychology trainees in an integrated OBGYN/substance use disorder outp	13
Perspectives on trauma and the design of a technology-based trauma-informed intervention for women receiving medications for addiction treatment in community-based settings	13
Alcohol screening and brief intervention in emergency departments: Review of the impact on healthcare costs and utilization	13
Using machine learning to identify predictors of imminent drinking and create tailored messages for at-risk drinkers experiencing homelessness	13
Competing risks of women and men who use fentanyl: “The number one thing I worry about would be my safety and number two would be overdose”	13
Health care-seeking experiences for people who inject drugs with hepatitis C: Qualitative explorations of stigma	13
Increased availability of telehealth mental health and substance abuse treatment for peripartum and postpartum women: A unique opportunity to increase telehealth treatment	13
National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness	13
Extended-release naltrexone for youth with opioid use disorder	13
Factors associated with psychotic symptoms among a sample of male prisoners with substance use disorder: A cross-sectional study	13
Mobile low-threshold buprenorphine integrated with infectious disease services	13
Substance use among women who are pregnant: Examining treatment completion by race and ethnicity	13
Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids	13
Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention	13
Benzodiazepine misuse in adults with alcohol use disorder: Prevalence, motives and patterns of use	12
Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities	12
Healthcare utilization of individuals with substance use disorders following Affordable Care Act implementation in a California healthcare system	12
Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder	12
What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings	12
Increasing access to family planning services among women receiving medications for opioid use disorder: A pilot randomized trial examining a peer-led navigation intervention	12

Long-acting depot buprenorphine in people who are homeless: Views and experiences	12
Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada	12
Substance use predictors of attendance among veterans in integrated PTSD and alcohol use disorder treatment	12
Characterizing trends in methamphetamine-related health care use when there is no ICD code for “methamphetamine use disorder”	12
Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing	12
Psychometric validation of an adaptation of the Penn Alcohol Craving Scale to assess aggregated drug craving	12
Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support	12
A randomized clinical trial of smartphone self-managed recovery support services	12
It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment	12
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)	12
Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges	12
Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration	12
Hepatitis C cascade of care at an integrated community facility for people who inject drugs	12
Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic	12
Parent SMART (Substance Misuse in Adolescents in Residential Treatment): Pilot randomized trial of a technology-assisted parenting intervention	11
Attitudes toward opioid use disorder pharmacotherapy among recovery community center attendees	11
Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults	11
Treatment admissions for opioids, cocaine, and methamphetamines among adolescents and emerging adults after legalization of recreational marijuana	11
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services	11
Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration	11
From policy to practice: Pilot program increases access to medication for opioid use disorder in rural Colorado	11
The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?	11
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail	11